Etrasimod, sold under the brand name Velsipity, is a medication that is used for the treatment of ulcerative colitis.[4] It is a selective sphingosine-1-phosphate (S1P) receptor modulator that modifies the activity of the immune system.[4] It is taken by mouth.[4]
The most common side effects include lymphopenia (low levels of lymphocytes) and headache.[6]
Etrasimod was discovered by Arena Pharmaceuticals, with subsequent development by Pfizer.[8] Etrasimod was approved for medical use in the United States in October 2023,[4] and in the European Union in February 2024.[6]
^"Therapeutic Goods (Poisons Standard—June 2024) Instrument 2024". Federal Register of Legislation. 30 May 2024. Retrieved 10 June 2024.
^"Regulatory Decision Summary for Velsipity". Drug and Health Products Portal. 31 January 2024. Retrieved 1 April 2024.
^"Notice: Multiple Additions to the Prescription Drug List (PDL) [2024-04-30]". Health Canada. 30 April 2024. Retrieved 3 May 2024.
^ abcde"Velsipity- etrasimod tablet, film coated". DailyMed. 16 November 2023. Retrieved 23 February 2024.
^"Velsipity- etrasimod tablet, film coated". DailyMed. 17 November 2023. Retrieved 23 February 2024.
^ abcCite error: The named reference Velsipity EPAR was invoked but never defined (see the help page).
^"Velsipity Product information". Union Register of medicinal products. 19 February 2024. Retrieved 23 February 2024.
^Bayer M (2 May 2023). "Pfizer tosses newly acquired meds out of the Arena". Fierce Biotech. Retrieved 13 October 2023.
Etrasimod, sold under the brand name Velsipity, is a medication that is used for the treatment of ulcerative colitis. It is a selective sphingosine-1-phosphate...
(formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371...
venules by blocking binding to MAdCAM-1. While the medications ozanimod and etrasimod inhibit the sphingosine-1-phosphate receptor to prevent T-cell migration...
NESS-040C5 Tedalinab "Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation"...